Cargando…
A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors
The U.S. Food and Drug Administration issued a guidance for pharmaceutical industry defining preapproval and postapproval requirements for the demonstration of cardiovascular (CV) safety for all new medications developed for glycemic management in type 2 diabetes. However, results published from the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166543/ https://www.ncbi.nlm.nih.gov/pubmed/30294582 http://dx.doi.org/10.4103/ijem.IJEM_104_18 |